Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative radiotherapy and temozolomide combined with tumor treating fields and apatinib for newly diagnosed glioblastoma
ChiCTR2100041969Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and temozolomide in glioblastoma (GBM), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival at 12 months. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
Rivoceranibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2100041969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041969.